CD8A and colorectal cancer: Wang et al. discovered that the inhibition of METTL3 or METTL14 can help colorectal cancer and melanoma cell acquire an enhanced immune response to anti-PD-1 therapy through increasing CD8 T cells and IFN-γ secretion [36].